SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 420
- Registration Number
- NCT06980272
- Locations
- 🇨🇳
The Shanghai East Hospital, Shanghai, China
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 154
- Registration Number
- NCT06944444
- Locations
- 🇨🇳
Shanghai First People's Hospital, Shanghai, Shanghai, China
Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies
Phase 2
Not yet recruiting
- Conditions
- Chemotherapy-induced AnemiaNon-myeloid Malignancies
- Interventions
- Drug: rhEPO
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 80
- Registration Number
- NCT06854276
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
Phase 1
Recruiting
- Conditions
- HyperuricemiaGout
- Interventions
- Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 60
- Registration Number
- NCT06629376
- Locations
- 🇨🇳
HuaShan Hospital Fudan University project, ShangHai, China, Shanghai, China
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
Phase 3
- Conditions
- Kidney Failure, ChronicHemodialysis
- Interventions
- Drug: Human Erythropoiesis Injection (CHO cell)Drug: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 300
- Registration Number
- NCT05211167
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Phase 1
- Conditions
- Liver Disease ChronicThrombocytopenia
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 54
- Registration Number
- NCT05193201
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Phase 1 Study of SSS17 in Healthy Subjects.
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 76
- Registration Number
- NCT04893187
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
Phase 3
- Conditions
- Uremic Pruritus
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 135
- Registration Number
- NCT04728984
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
A Study of SSS17 in Healthy Subjects
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 65
- Registration Number
- NCT04317833
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
Phase 4
Completed
- Conditions
- ITP
- Interventions
- Drug: TPO
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 288
- Registration Number
- NCT04089267
- Locations
- 🇨🇳
Xinxiang Central Hospital,, Xinxiang, China
🇨🇳renmin Hospital of Wuhan University Hubei General Hospital, Wuhan, Hubei, China
🇨🇳Loudi Central Hospital, Loudi, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath